Dragon Pharmaceutical und Oriental Wave - Neuigkeiten??? - 500 Beiträge pro Seite

[UserTom]

Es ist so still um Dragon Pharmaceutical geworden. Seit dem 14.01.2005 gab es irgendwie keinerlei Neuigkeiten mehr zu diesem kanadischen / chinesischen Biotech-Unternehmen. Die letzte Meldung war, dass Dragon die Übernahme von Oriental Wave (China) abgeschlossen habe. Seitdem weist der Chartverlauf eine Seitwärtsbewegung auf. Dabei treten häufig während des Tages große Kursschwankungen auf. Man hat den Eindruck, niemand weiß was er von Dragon im Moment halten soll.

Noch mal zur Erinnerung: Vor einiger Zeit wurde die Übernahme von Oriental Wave Holding angekündigt, wodurch aus dem kleinen Biotech-Unternehmen ein erheblich größeres Unternehmen wird, da der Übernahmekanditat nicht gerade klein ist.

Mittlerweile ist bezüglich der Übernahme eigentlich alles schon gelaufen: Die Aktionäre haben zugestimmt, das Board of Directors wurde erweitert, usw.

Die Aktie selbst zeigt allerdings keinerlei Richtungsänderung an.

[UserTom]

Gestern hat das Unternehmen Ergebnisse gemeldet:

In 2004 wurde ein Umsatz von 3,71 Mio USD verglichen mit 3,65 Mio USD im Vorjahr erreicht. Der Nettoverlust konnte in 2004 auf 0,94 Mio USD oder 0,05 USD pro Aktie reduziert werden. Im Vorjahr fiel noch ein höherer Verlust von 1,99 Mio oder 0,10 USD pro Aktie an.

[js200]

DRUG: Announces Proposed Private Placement of $25M

Wednesday, March 30, 2005 18:43 ET

Dragon Pharmaceuticals Inc (OTCBB: DRUG) announced that it proposes to offer on a best efforts basis up to $25M of its securities in a private placement to accredited investors. The type of securities, price and completion of the proposed private placement will depend on, among other things, market conditions. It is anticipated that the proceeds from the private placement will be used to serve as the working capital to ramp up the production of the newly operated Chemical division, to improve the Company`s financial structure and to fund the Company`s EPO market development in Europe as well as the relocation of the Biotech facility within China.

[UserTom]

Danke js200. Auf diese Nachricht bin ich mittlerweile auch gestoßen.

Auf der Homepage ist sogar schon die neue Struktur nachvollzogen worden: Chemie, Biotech und Pharma.

http://www.dragonbiotech.com/

[UserTom]

Dragon Announces Appointment of General Manager of Chinese Operations



Vancouver, BC- May 4, 2005. Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD) today announced the appointment of Mr. Xiaochun Zhang as the General Manager of the Company’s Chinese operations.

As the General Manager of our Chinese operations, Mr. Zhang is responsible for the overall operational and sales and marketing management of the Pharma and Chemical divisions. Such responsibilities will be extended to cover the Biotech division after its relocation from its current location in Nanjing city.

Mr. Zhang has 20 years of expertise in large-scale fermentation processes as a chemical engineer together with operational experience with various Chinese and international pharmaceutical companies. Prior to joining Dragon, Mr. Zhang was the Deputy General Manager of Aurobindo Bio-pharma Co. Ltd. in Datong, China, a subsidiary of one of the largest pharmaceutical companies in India. Mr. Zhang started his career as an engineer in the fermentation workshop in Zhangjiakou Pharmaceutical Co. Ltd., and became the Deputy General Manager of the company in 1997. In the same year, Mr. Zhang was appointed as the General Manager of GIST-Brocades Pharmaceutical Ltd., a joint venture in China between Zhangjiakou Pharmaceutical Co. Ltd. and Netherlands?DSM, one of largest chemical companies in the world.

Mr. Zhang holds a Bachelor degree in chemical mechanical engineering from Hebei University of Technology and is currently participating in an Executive MBA program from the Helsinki School of Economics and Business Administration. Mr. Zhang is based in our office in Datong city, China.

[UserTom]

Gestern hat Dragon erschreckenderweise seine Unterstützung von 0,80 USD aufgegeben und hat schließlich mit 0,75 USD geschlossen. Das ganze geschah auch noch unter hohen Umsätzen - also zumindest verglichen mit den vorherigen Tagen, wo die Umsätze meist nicht mal in den vierstelligen Bereich gingen. Gestern dagegen wurden immerhin 37.460 Aktien umgesetzt.

Ich habe daraufhin mal die Nachrichtenlage überprüft und bin auf folgende Neuigkeit gestoßen (die allerdings auf den gestrigen Kursverlauf noch keine Auswirkungen haben konnte).

Nachbörslich hat das Unternehmen nämlich Ergebnisse vermeldet, die eigentlich den Kurs heute beflügeln müssten. So konnten allein die Umsätze der Chemiesparte um das 5,5 fache verglichen zur Vorjahresperiode gesteigert werden. Der Nettogewinn lag bei 0,02 USD verglichen mit 0,04 USD in der Vorjahresperiode. Wahrscheinlich kann man das aber nicht miteinander vergleichen, da Dragon zwischenzeitlich die Übernahme von Oriental Wave Holding Limited abgeschlossen hat.

Nachlesen kann man den kompletten Bericht übrigens auf der Website des Unternehmens. Ich muss gestehen, ich habe ihn selbst noch nicht komplett durchgelesen. Bin mal gespannt, ob er noch weitere interessante Details enthält.

[UserTom]

Dragon Announces Results of the Annual General Meeting
Vancouver, BC- August 15, 2005. - Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD) ("the Company") is pleased to announce the results of the Annual Shareholders’ Meeting held on August 12, 2005.

There were 54,818,706 shares equaling 87.20% of the outstanding shares represented at this meeting. All of the following proposals were approved by a substantial majority of votes:

- Election of Mr. Yanlin Han, Dr. Alexander Wick, Ms Xuemei Liu, Mr. Zhanguo Weng, and Dr. Yiu Kwong Sun as the directors;

- Amendment to Certificate of Incorporation to eliminate Article VII which states a specified number of directors;

- Amendment to the By-laws of the Company to allow the Board of Directors to set the number of directors at a range from 1 to 11;

- Adoption of 2005 Stock Option Plan.

“We are very pleased to see the support of our shareholders on all proposals” said by Yanlin Han, Chairman and CEO of the Company, “The amendments to our by-laws and Certificate of Incorporation will allow us to expand our board and appoint additional directors. We intend to appoint additional independent board members to meet the American Stock Exchange (AMEX) listing standard, which requires a majority of the Board to be independent directors. In addition, we intend to establish an audit committee and a compensation committee consisting of solely independent directors. The Company is in the final stage of searching for appropriate individuals as the independent Board members who will bring along their valuable experience and creditability for the Company to move forward.”


About Dragon Pharmaceutical Inc.
Incorporated in Florida, USA, Dragon Pharmaceutical Inc. is an international pharmaceutical company headquartered in Vancouver, Canada, with three key business units consisting of a Pharma division for 52 generic prescription, over-the-counter and sterilized bulk drugs; a Chemical division for bulk pharmaceutical chemicals and intermediates (Clavulanic Acid and 7-ACA); and a Biotech division for recombinant drugs (EPO and G-CSF). The Company has four manufacturing facilities in China (three in Datong city and one in Nanjing city), approximately 1,800 employees, plus over 1,200 sales representatives in China, and approximately 58 key products in 90 different dosages and presentations currently in market.

[UserTom]

Hier ein Auszug aus den Quartalszahlen zum 2. Quartal 2005. Nach der Oriental Übernahme kann Dragon nun so richtig loslegen. Neben den ungeheuren Kapazitätserweitungen hat Dragon außerdem gezeigt, dass sie nun ein international tätiges Unternehmen sind. Nun fehlt eigentlich nur noch das Listing an einem geregelten Markt (z.B. Amex, NYSE), damit das Unternehmen sein Pink Sheet Image (OTC) verliert und endlich auch mal größere Stückzahlen gehandelt werden.

Dragon Pharmaceutical Announces Financial Results for the Second Quarter of 2005

Vancouver, BC- September 21, 2005. Dragon Pharmaceutical Inc. ("Dragon" or the "Company")(TSX: DDD; OTC BB: DRUG) today announced the financial results for the second quarter of 2005.

Due to Dragon`s acquisition of Oriental Wave Holding Limited ("Oriental Wave") on January 12, 2005 being deemed a reverse take-over transaction, the following discussion reflects the Company`s results of operations for the quarter ended June 30, 2005 while discussions on the quarter ended June 30, 2004 only reflect the results of Oriental Wave`s Pharma and Chemical businesses. In addition, discussions regarding the six month results ended June 30, 2004 and 2005 were based on the restated financials. (Please refer to a separate press release and the Company`s 1Q-QSB filing for details) The Company`s financial statements comply with U.S. GAAP (Generally Accepted Accounting Principles) and all dollar amounts are expressed in U.S. currency. The full financial statements will also be available on Dragon`s website at www.dragonpharma.com.

Sales for the second quarter ended June 30, 2005 increased 55% to USD 11.35 million from USD 7.32 million for the same period in 2004. Sales for the first six months of 2005 were USD 23.18 million as compared to USD 14.48 million for the same period in 2004, representing a 60% year-over-year growth rate. The increase in sales was due to the expansion of sales from the Chemical Division and the inclusion of the sales from the Biotech Division.

Gross profit and gross margin for the three months ended June 30, 2005 were USD 3.18 million and 28% compared to USD 4.04 million and 55% for the same period of 2004. The Company recorded a net loss of USD 0.003 million or USD 0.00 per share for the three months ended June 30, 2005 compared to a net income of USD 2.34 million, after restatement, or USD 0.05 per share for the same period in 2004. Gross profit and gross margin for the six months ended June 30, 2005, were USD 6.39 million and 28% compared to USD 7.23 million and 50% for the same period of 2005. Net income for the six months ended June 30, 2005 was USD 1.24 million or 0.02 per share compared to a net income of USD 4.28 million or 0.10 per share for the same period of 2004. Gross profit and net income was lower than the same period of 2004 because of the change in product mix especially with the significant increase in sales of the Chemical Division whose facilities were constructed and completed in 2004 and is currently at the ramp-up stage of production which incurs higher per unit production and operation cost, especially depreciation expenses. In addition, the operating expenses for the three and six months ended June 30, 2005 were USD 2.77 million and USD 5.16 million, respectively, compared to USD 1.36 million and USD 2.60 million, respectively, for the same period of 2004. The increase in operating expense reflects the increase overheads related to the operations of all three divisions and the offices in Canada and Switzerland, while for the same period of 2004, only Pharma Division and one of the two facilities of the Chemical Division were in operation.

During the second quarter of 2004, 100% of total sales were generated from the Chinese market. However, with the addition of the international sales from the Biotech Division, and the export of products from the Chemical Division during the second quarter of 2005, 7.5% of the total sales were generated from the international markets while 92.5% of the sales were generated from the Chinese market. The contribution of sales from the international markets has been increasing and is expected to continue as the Company continues to increase commercialization of its products outside of China.